enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. Merck-AstraZeneca breast cancer drug reduces risk of ... - AOL

    www.aol.com/finance/merck-astrazeneca-breast...

    Lynparza patients had a 79.6% IDFS rate at six years, compared to 70.3% for placebo patients, with the drug reducing the risk of invasive breast cancer recurrence, second cancers, or death by 35%.

  3. Home medical equipment - Wikipedia

    en.wikipedia.org/wiki/Home_medical_equipment

    Home medical equipment is a category of devices used for patients whose care is being managed from a home or other private facility managed by a nonprofessional caregiver or family member. It is often referred to as "durable" medical equipment (DME) as it is intended to withstand repeated use by non-professionals or the patient, and is ...

  4. ‘No one should have to be fighting cancer and insurance at ...

    www.aol.com/no-one-fighting-cancer-insurance...

    Diagnosed with leukemia three years ago, Tsoukalas, 26, was stunned to learn that her insurer’s coverage of the drug she needed came with a $13,000 monthly copay, which the recent college ...

  5. Accredo - Wikipedia

    en.wikipedia.org/wiki/Accredo

    Accredo Health Group, Inc. is a specialty pharmaceutical and service provider for patients with complex and chronic health conditions. [1] Accredo provides specialty drugs, drugs that cost more than $600 per month, with the average being $10,000 a month, which treat serious conditions such as multiple sclerosis, rheumatoid arthritis, hemophilia and cancer. [1]

  6. Cancer Therapy Advisor - Wikipedia

    en.wikipedia.org/wiki/Cancer_Therapy_Advisor

    Cancer Therapy Advisor (formerly Chemotherapy Advisor) is an online resource and quarterly medical news publication for oncology healthcare professionals, with updated treatment regimens for patients with cancer and live medical conference coverage.

  7. AstraZeneca's Investigational Cancer Drug Disappoints In Late ...

    www.aol.com/astrazenecas-investigational-cancer...

    In the prespecified subgroup of patients with nonsquamous NSCLC, datopotamab deruxtecan showed a 2.3-month improvement in OS compared to docetaxel (14.6 vs. 12.3 months).

  8. 340B Drug Pricing Program - Wikipedia

    en.wikipedia.org/wiki/340B_Drug_Pricing_Program

    However, the consequences are increased Medicare payments and beneficiary coinsurance, as well as additional competition for community-based practices...For oncology practices, one reason cited for the growth is the opportunity to expand the patient base for drugs purchased under the 340B discount drug purchase plan.

  9. Civica Rx - Wikipedia

    en.wikipedia.org/wiki/Civica_Rx

    Civica Rx is a nonprofit generic drug company founded in 2018 by leading U.S. health systems and philanthropies [1] for the purpose of preventing and mitigating drug shortages in the United States, and the price hikes that can accompany them. [2] Civica's mission is to make quality generic medicines accessible and affordable to everyone.